Minerva Neurosciences Appoints Carlos Martin as Chief Commercial Officer for Strategic Growth

Neurvati Neurosciences Strengthens Leadership with Appointment of Chief Commercial Officer

Neurvati Neurosciences, a subsidiary of Blackstone Life Sciences, announces the appointment of Carlos Martin as Chief Commercial Officer (CCO), effective November 13, 2025. With over 20 years of experience in the biopharmaceutical sector, Martin brings a wealth of knowledge in commercial organization building and the launch of innovative therapies across various therapeutic areas, including gene therapy, oncology, and rare diseases. His previous role as CCO at Rocket Pharmaceuticals showcased his ability to transition a company from clinical-stage to commercial readiness, where he implemented successful commercialization strategies within the U.S., European, and Japanese markets.

Under the leadership of Bruce Leuchter, M.D., President & CEO of Neurvati, the creation of the CCO role reflects the company’s strategic focus on integrating commercial considerations early into its development programs. Leuchter emphasizes that Martin’s background in innovative therapeutic areas is essential for translating scientific advancements into market success. This proactive approach aims to enhance the overall value proposition of Neurvati’s neuroscience therapies for various stakeholders, including patients, healthcare providers, payors, and health systems. By embedding commercial strategies into their operational framework, Neurvati positions itself to maximize the impact of its products in the marketplace.

Martin expresses enthusiasm for his new role, highlighting his commitment to building a global commercial framework that will facilitate the effective delivery of Neurvati’s therapies to those who need them most. This strategic appointment aligns with Neurvati’s mission to advance clinically validated programs that promise significant patient impact and substantial market value. By preparing for successful product launches well in advance, the company aims to ensure its innovative therapies reach the patients they are designed to benefit, reinforcing its dedication to enhancing healthcare outcomes in the field of neuroscience.

In addition to the leadership change, this strategic move underscores Neurvati's commitment to addressing unmet medical needs within the neuroscience domain. The company’s focus on innovative therapeutic solutions, combined with a strong commercial strategy, positions it favorably in the competitive biopharmaceutical landscape.

As Neurvati works towards the commercialization of its therapies, the integration of experienced leadership like Martin’s is expected to play a crucial role in navigating the complexities of the market and in achieving successful product launches in the coming years.